Unfortunately there are still a large number of people dying of COVID-19 <65 years old according to CDC records in the USA... and it is unknown if an increased dose of Remestemcel-L will in fact help patients older than 65 but at least they should give that a try IMO .....
An additional COVID-19 ARDS trial could be split with an <65yo cohort and an >65yo cohort with an increased dose for the latter to see what transpires ?
Many on here who say stems are too expensive or are not the answer obviously are ok with hundreds of thousands of people under 65 dying of COVID-19 while at the same time failing to recognise the extraordinary costs associated with end of life in ICU for COVID-19 victims or the fact that death is absolute .... [shakes head]
GLTAH
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#AgeAndSex
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-92
-
- There are more pages in this discussion • 814 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |